Cochlear Limited Selects AMI Semiconductor to Co-Design and Manufacture Future Generation DSP Based System-on-Chip for Cochlear
28 November 2006 - 12:00AM
Business Wire
AMI Semiconductor (NASDAQ:AMIS), a leading designer and
manufacturer of state-of-the-art integrated mixed-signal and
structured digital products for the automotive, medical and
industrial markets, today announced that Cochlear Limited
(ASX:COH), the worldwide leading designer and manufacturer of
cochlear implants for hearing loss, has selected AMIS as its
semiconductor co-design and manufacturing partner for its future
generation DSP-based system-on-chip. Cochlear implants are a proven
treatment for severe-to-profound hearing loss in adults and
children. The surgically implanted electronic device bypasses
damaged hair cells and stimulates the hearing nerve fibres directly
inside the cochlea, providing useful hearing and improved
communication abilities to the wearer. External components include
a sound processor and transmitter that relay processed signals to
the implant using electromagnetic induction. Placed under the skin
behind the ear, the implanted components include a receiver and an
electrode-array that is placed into the cochlea to stimulate
precise locations on the auditory nerve. Cochlear Limited�s current
generation Nucleus Freedom� system was approved by the U.S. Food
and Drug Administration (FDA) in March 2005 and is implanted in
over 12,000 patients worldwide. �Technical leadership and
continually advancing the hearing performance, reliability and
usability of our devices is fundamental to our strategy,� said Jan
Janssen, senior vice president of design and development at
Cochlear. �With proven expertise in advanced mixed-signal
technologies, deep knowledge of audiological technical requirements
and a solid body of existing semiconductor IP, we chose AMI
Semiconductor as a technology partner. We believe that with the
help of AMIS, we will introduce new capabilities, offering an
enhanced quality of life for people with severe to profound hearing
loss.� �We are thrilled to form a technology partnership with
Cochlear. Their track record of innovation is truly impressive,�
said Todd Schneider, vice president of the medical group at AMIS.
�Cochlear implants continue to be the largest segment of the neural
prostheses category of neurostimulation medical devices and an area
where we�ve developed specific expertise and innovative solutions.
This relationship reinforces our belief that customers value a
dependable and highly flexible partner dedicated to meeting the
specific semiconductor needs of the medical device market.� About
AMI Semiconductor AMI Semiconductor (AMIS) is a leader in the
design and manufacture of silicon solutions for the real world. As
a widely recognized innovator in state-of-the-art integrated
mixed-signal and structured digital products, AMIS is committed to
providing customers with the optimal value, quickest time-to-market
semiconductor solutions. Offering unparalleled manufacturing
flexibility and dedication to customer service, AMI Semiconductor
operates globally with headquarters in Pocatello, Idaho, European
corporate offices in Oudenaarde, Belgium, and a network of sales
and design centers located in the key markets of North America,
Europe and the Asia Pacific region. About Cochlear Limited Cochlear
is the global leader in the development, manufacture and marketing
of innovative implantable hearing solutions. Products include the
Nucleus range of Cochlear implant systems and the Baha implant
system, a bone conduction implant designed to help those with
conductive hearing loss, mixed hearing loss and single sided
deafness. Headquartered in Sydney, Australia, Cochlear is an
Australian Stock Exchange traded public company with over 1100
employees globally. Additional information about Cochlear can be
found at www.cochlear.com. AMI Semiconductor (NASDAQ:AMIS), a
leading designer and manufacturer of state-of-the-art integrated
mixed-signal and structured digital products for the automotive,
medical and industrial markets, today announced that Cochlear
Limited (ASX:COH), the worldwide leading designer and manufacturer
of cochlear implants for hearing loss, has selected AMIS as its
semiconductor co-design and manufacturing partner for its future
generation DSP-based system-on-chip. Cochlear implants are a proven
treatment for severe-to-profound hearing loss in adults and
children. The surgically implanted electronic device bypasses
damaged hair cells and stimulates the hearing nerve fibres directly
inside the cochlea, providing useful hearing and improved
communication abilities to the wearer. External components include
a sound processor and transmitter that relay processed signals to
the implant using electromagnetic induction. Placed under the skin
behind the ear, the implanted components include a receiver and an
electrode-array that is placed into the cochlea to stimulate
precise locations on the auditory nerve. Cochlear Limited's current
generation Nucleus Freedom(TM) system was approved by the U.S. Food
and Drug Administration (FDA) in March 2005 and is implanted in
over 12,000 patients worldwide. "Technical leadership and
continually advancing the hearing performance, reliability and
usability of our devices is fundamental to our strategy," said Jan
Janssen, senior vice president of design and development at
Cochlear. "With proven expertise in advanced mixed-signal
technologies, deep knowledge of audiological technical requirements
and a solid body of existing semiconductor IP, we chose AMI
Semiconductor as a technology partner. We believe that with the
help of AMIS, we will introduce new capabilities, offering an
enhanced quality of life for people with severe to profound hearing
loss." "We are thrilled to form a technology partnership with
Cochlear. Their track record of innovation is truly impressive,"
said Todd Schneider, vice president of the medical group at AMIS.
"Cochlear implants continue to be the largest segment of the neural
prostheses category of neurostimulation medical devices and an area
where we've developed specific expertise and innovative solutions.
This relationship reinforces our belief that customers value a
dependable and highly flexible partner dedicated to meeting the
specific semiconductor needs of the medical device market." About
AMI Semiconductor AMI Semiconductor (AMIS) is a leader in the
design and manufacture of silicon solutions for the real world. As
a widely recognized innovator in state-of-the-art integrated
mixed-signal and structured digital products, AMIS is committed to
providing customers with the optimal value, quickest time-to-market
semiconductor solutions. Offering unparalleled manufacturing
flexibility and dedication to customer service, AMI Semiconductor
operates globally with headquarters in Pocatello, Idaho, European
corporate offices in Oudenaarde, Belgium, and a network of sales
and design centers located in the key markets of North America,
Europe and the Asia Pacific region. About Cochlear Limited Cochlear
is the global leader in the development, manufacture and marketing
of innovative implantable hearing solutions. Products include the
Nucleus range of Cochlear implant systems and the Baha implant
system, a bone conduction implant designed to help those with
conductive hearing loss, mixed hearing loss and single sided
deafness. Headquartered in Sydney, Australia, Cochlear is an
Australian Stock Exchange traded public company with over 1100
employees globally. Additional information about Cochlear can be
found at www.cochlear.com.
Cochlear (ASX:COH)
Historical Stock Chart
From Jun 2024 to Jul 2024
Cochlear (ASX:COH)
Historical Stock Chart
From Jul 2023 to Jul 2024